Track topics on Twitter Track topics that are important to you
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Our pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications.
Oncothyreon is headquartered in Seattle, Washington. The Company is traded on the NASDAQ National Market under the symbol ONTY.
Small molecule pipeline:
PX-866 Targets the Phosphatidylinositol-3-kinase (PI-3K) Pathway
PX-866 is a small molecule drug that irreversibly inhibits phosphatidylinositol-3-kinase (PI-3K), a family of intracellular signaling molecules that play essential roles in multiple cellular functions. In normal cells the PI-3K pathway is tightly controlled, whereas the inappropriate activation of PI-3K is important in the pathogenesis of multiple human cancers, making it a rational and attractive target for drug development.
ONT-701 is a pan-inhibitor of the B-cell lymphoma-2, or Bcl-2, family of anti-apoptotic proteins. Overexpression of one or more members of the Bcl-2 family of proteins is common in most human cancers.
ONT-701 and related compounds were obtained through an exclusive licensing agreement with the Sanford-Burnham Medical Research Institute. ONT-710 is currently in preclinical development.
L-BLP25 (formerly Stimuvax®) is a therapeutic vaccine designed to stimulate an individual's immune system to recognize cancer cells and control the growth and spread of cancers in order to increase the survival of cancer patients. L-BLP25 incorporates a 25-amino acid sequence of the cancer-associated marker MUC-1 in a liposomal formulation. The vaccine is thought to work by stimulating a T-cell mediated immune response to cancer cells expressing the target MUC-1.
2601 Fourth Avenue
Phone: (206) 801-2100
Fax: (206) 801-2101
May 2013 Array BioPharma (ARRY) entered into a Development and Commercialization Agreement with Oncothyreon (ONTY) to collaborate on development and commercialization of ONT380 for the treatment of ca...
Oncothyreon is a biotechnology company dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients. We are currently developing multiple therapeutic ...
Alpine BioVentures is a venture capital firm committed to investing in and building revolutionary healthcare companies. It brings a unique perspective to identify game-changing sc...
We have published hundreds of Oncothyreon Inc. news stories on BioPortfolio along with dozens of Oncothyreon Inc. Clinical Trials and PubMed Articles about Oncothyreon Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oncothyreon Inc. Companies in our database. You can also find out about relevant Oncothyreon Inc. Drugs and Medications on this site too.
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...